Terms: = Lung cancer AND TSC2, FLJ43106, 7249, ENSG00000103197, LAM, tuberin, TSC4 AND Treatment
186 results:
1. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract] [Full Text] [Related]
2. Sporadic Lymphangioleiomyomatosis Disease: A Case Report.
Nikmanesh Y; Shokripour M; Mokhtari M; Khazayi M; Monabati A; Rezayi R; Bahtouee M
Iran J Med Sci; 2023 Sep; 48(5):516-521. PubMed ID: 37786468
[TBL] [Abstract] [Full Text] [Related]
3. [Expert consensus on the diagnosis and management of Birt-Hogg-Dubé syndrome].
; ; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Sep; 46(9):897-908. PubMed ID: 37670643
[TBL] [Abstract] [Full Text] [Related]
4. lamC2 promotes EGFR cell membrane localization and acts as a novel biomarker for tyrosine kinase inhibitors (TKIs) sensitivity in lung cancer.
Tong D; Wang X; Liu L; Wen T; Chen Q; Huang C
Cancer Gene Ther; 2023 Nov; 30(11):1498-1512. PubMed ID: 37542131
[TBL] [Abstract] [Full Text] [Related]
5. Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet.
Gibbons E; Minor BMN; Hammes SR
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37410387
[TBL] [Abstract] [Full Text] [Related]
6. Tissue-Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition.
Pietrobon A; Yockell-Lelièvre J; Melong N; Smith LJ; Delaney SP; Azzam N; Xue C; Merwin N; Lian E; Camacho-Magallanes A; Doré C; Musso G; Julian LM; Kristof AS; Tam RY; Berman JN; Shoichet MS; Stanford WL
Adv Sci (Weinh); 2023 Sep; 10(26):e2302611. PubMed ID: 37400371
[TBL] [Abstract] [Full Text] [Related]
7. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.
Boilève A; Faron M; Fodil-Cherif S; Bayle A; Lamartina L; Planchard D; Tselikas L; Kanaan C; Scoazec JY; Ducreux M; Italiano A; Baudin E; Hadoux J
Eur J Cancer; 2023 Jun; 186():122-132. PubMed ID: 37062210
[TBL] [Abstract] [Full Text] [Related]
8. Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.
Astrinidis A; Li C; Zhang EY; Zhao X; Zhao S; Guo M; Olatoke T; Mattam U; Huang R; Zhang AG; Pitstick L; Kopras EJ; Gupta N; Jandarov R; Smith EP; Fugate E; Lindquist D; Markiewski MM; Karbowniczek M; Wikenheiser-Brokamp KA; Setchell KDR; McCormack FX; Xu Y; Yu JJ
JCI Insight; 2023 May; 8(9):. PubMed ID: 36927688
[TBL] [Abstract] [Full Text] [Related]
9. mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer.
Kumari A; Gesumaria L; Liu YJ; Hughitt VK; Zhang X; Ceribelli M; Wilson KM; Klumpp-Thomas C; Chen L; McKnight C; Itkin Z; Thomas CJ; Mock BA; Schrump DS; Chen H
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36883564
[TBL] [Abstract] [Full Text] [Related]
10. Predicting Individualized lung Disease Progression in treatment-Naive Patients With Lymphangioleiomyomatosis.
Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
[TBL] [Abstract] [Full Text] [Related]
11. Clinical features and outcomes of male patients with lymphangioleiomyomatosis: A review.
Zhang H; Hu Z; Wang S; Wu K; Yang Q; Song X
Medicine (Baltimore); 2022 Dec; 101(52):e32492. PubMed ID: 36596036
[TBL] [Abstract] [Full Text] [Related]
12. Tuberous Sclerosis Complex: Genetic counselling and perinatal follow-up.
Touraine R; Hauet Q; Harzallah I; Baruteau AE
Arch Pediatr; 2022 Dec; 29(5S):5S3-5S7. PubMed ID: 36585068
[TBL] [Abstract] [Full Text] [Related]
13. Lymphangioleiomyomatosis: a metastatic lung disease.
Kundu N; Holz MK
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
[TBL] [Abstract] [Full Text] [Related]
14. Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (lam).
Li F; Zhang Y; Lin Z; Yan L; Liu Q; Li Y; Pei X; Feng Y; Han X; Yang J; Zheng F; Li T; Zhang Y; Fu Z; Shao D; Yu J; Li C
Cell Death Dis; 2022 Dec; 13(12):1065. PubMed ID: 36543771
[TBL] [Abstract] [Full Text] [Related]
15. An RNA-seq transcriptome analysis for investigating the anti-lung cancer activity of medicinal
Maimaiti A; Xu J; Shi L
Br J Nutr; 2023 Sep; 130(5):737-749. PubMed ID: 36468438
[No Abstract] [Full Text] [Related]
16. Pulmonary lymphangioleiomyomatosis and renal angiomyolipoma in a patient with systemic lupus erythematosus: A case report.
Koh JS; Oh S; Chung C
Medicine (Baltimore); 2022 Sep; 101(38):e30554. PubMed ID: 36197220
[TBL] [Abstract] [Full Text] [Related]
17. Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.
Chang S; Choi JS; Leem AY; Lee SH; Lee SH; Kim SY; Chung KS; Jung JY; Kang YA; Kim YS; Lee JG; Paik HC; Shim HS; Lee EH; Park MS
Sci Rep; 2022 May; 12(1):8260. PubMed ID: 35585116
[TBL] [Abstract] [Full Text] [Related]
18. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant.
Warrior K; Leard LE; Nair AR; Gries CJ; Fisher AJ; Johnson SR; McCormack FX; Dilling DF
Respir Med; 2022; 195():106779. PubMed ID: 35276437
[TBL] [Abstract] [Full Text] [Related]
19. Loss of
Huang Q; Li F; Hu H; Fang Z; Gao Z; Xia G; Ng WL; Khodadadi-Jamayran A; Chen T; Deng J; Zhang H; Almonte C; Labbe K; Han H; Geng K; Tang S; Freeman GJ; Li Y; Chen H; Wong KK
Sci Adv; 2022 Feb; 8(5):eabi9533. PubMed ID: 35119931
[TBL] [Abstract] [Full Text] [Related]
20. Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice.
Thomas A; Sumughan S; Dellacecca ER; Shivde RS; Lancki N; Mukhatayev Z; Vaca CC; Han F; Barse L; Henning SW; Zamora-Pineda J; Akhtar S; Gupta N; Zahid JO; Zack SR; Ramesh P; Jaishankar D; Lo AS; Moss J; Picken MM; Darling TN; Scholtens DM; Dilling DF; Junghans RP; Le Poole IC
JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34806651
[TBL] [Abstract] [Full Text] [Related]
[Next]
